When do the CALCITRIOL patents expire, and when will generic CALCITRIOL be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Parenteral	CALCITRIOL	calcitriol	INJECTABLE;INJECTION	075823-002	Mar 31, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Anda Repository	CALCITRIOL	calcitriol	SOLUTION;ORAL	203973-001	Jul 28, 2023	AA	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289-002	Jun 14, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fresenius Medcl	CALCITRIOL	calcitriol	INJECTABLE;INJECTION	075766-001	Feb 20, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Calcitriol, the active form of Vitamin D, is a critical therapeutic agent with established roles in calcium and phosphate homeostasis, bone metabolism, and immune modulation. Its primary indications include the management of hypocalcemia in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism, as well as Paget's disease of bone and familial hypophosphatemic rickets. The market for calcitriol is characterized by generic competition, but its therapeutic necessity in specific patient populations ensures continued demand. Emerging research into calcitriol's potential in oncology and autoimmune diseases presents future growth avenues, albeit with significant clinical and regulatory hurdles. Investment analysis requires a deep understanding of existing market dynamics, patent expirations, competitive landscape, and the R&D pipeline for new indications.

What are the Current Market Applications of Calcitriol?

Calcitriol is primarily prescribed to address conditions related to disordered calcium and phosphate metabolism. Its efficacy stems from its ability to mimic the endogenous hormone, stimulating intestinal absorption of calcium and phosphate, promoting bone mineralization, and suppressing parathyroid hormone (PTH) secretion.

Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism: This is the largest market segment for calcitriol. In CKD patients, impaired kidney function leads to reduced production of active Vitamin D and accumulation of phosphate, resulting in secondary hyperparathyroidism and renal osteodystrophy. Calcitriol therapy aims to normalize PTH levels, improve calcium and phosphate balance, and mitigate bone disease progression. The U.S. Food and Drug Administration (FDA) approved indications include the treatment of hyperparathyroidism and resultant bone disease in patients with moderate to severe CKD not yet on dialysis, and in dialysis patients [1].
Hypocalcemia: Calcitriol is used to treat hypocalcemia in various settings, including hypoparathyroidism and Vitamin D deficiency states.
Paget's Disease of Bone: This chronic disorder characterized by abnormal bone remodeling can be managed with calcitriol to help normalize calcium levels and reduce bone turnover.
Familial Hypophosphatemic Rickets: This genetic disorder, characterized by impaired phosphate reabsorption in the kidneys and rickets, is treated with calcitriol to improve bone mineralization and growth.

The established therapeutic role in these chronic conditions drives consistent demand, forming the foundation of the calcitriol market.

What is the Intellectual Property Landscape for Calcitriol?

The original patents for calcitriol have long since expired. As a small molecule synthesized decades ago, calcitriol itself is off-patent and available as a generic medication.

Original Synthesis and Discovery: The synthesis and identification of calcitriol as the active metabolite of Vitamin D were significant scientific achievements, leading to foundational patents that are now public domain.
Formulation Patents: While the molecule is generic, there may be extant patents covering specific pharmaceutical formulations, delivery systems (e.g., novel oral formulations, intravenous preparations, topical applications), or manufacturing processes designed to improve stability, bioavailability, or patient compliance. These patents, if present and valid, could offer a limited period of market exclusivity for specific branded or enhanced generic products.
Method of Use Patents: Patents covering new uses or indications for calcitriol are a potential area for intellectual property protection. However, establishing novelty and non-obviousness for an established drug requires robust clinical data demonstrating a significant and unexpected therapeutic benefit in a new disease context.

The absence of broad patent protection for the calcitriol molecule itself means that competition is primarily driven by manufacturing efficiency, cost, and established physician and patient relationships.

Who are the Key Market Players and What is Their Market Share?

The calcitriol market is highly fragmented due to the generic nature of the active pharmaceutical ingredient (API). Several manufacturers produce calcitriol, leading to competitive pricing.

Generic Manufacturers: A multitude of generic pharmaceutical companies supply calcitriol products globally. Examples include companies specializing in vitamins and endocrine therapies. Specific market share data is dynamic and proprietary, but the top players are typically those with established manufacturing capabilities, robust distribution networks, and strong relationships with pharmacies and healthcare systems.
Branded Products (Historically): While largely supplanted by generics, historically, branded calcitriol products played a significant role. Companies like AbbVie (formerly Abbott) with its brand Rocaltrol® were pioneers. These branded products often commanded premium pricing due to early market entry and physician familiarity. However, with generic entry, their market dominance has diminished considerably.
API Suppliers: Companies that manufacture the calcitriol API are crucial to the supply chain. Competition among API suppliers influences the cost of finished drug products.

The market is characterized by price-sensitive purchasing decisions, especially within large healthcare systems and pharmacy benefit management formularies.

What is the Competitive Landscape for Calcitriol Therapies?

The competitive landscape for calcitriol is multi-faceted, encompassing direct generic competition, alternative therapies for its primary indications, and potential future competition from novel agents.

Direct Generic Competition: This is the most significant competitive force. Numerous generic versions of oral and intravenous calcitriol are available, leading to price erosion and limiting opportunities for significant revenue growth from existing indications.
Other Vitamin D Analogues: While calcitriol is the active form, other Vitamin D analogues are used therapeutically.
- Ergocalciferol (Vitamin D2) and Cholecalciferol (Vitamin D3): These are dietary forms of Vitamin D used to treat deficiency. They require hepatic and renal activation to become calcitriol, making them less potent and slower-acting than direct calcitriol for severe metabolic disorders.
- Calcipotriol (Calcipotriene): A synthetic Vitamin D analogue primarily used topically for psoriasis. While chemically similar, its therapeutic application and systemic effects differ from calcitriol.
- Paricalcitol and Doxercalciferol: These are newer Vitamin D analogues specifically developed for the treatment of secondary hyperparathyroidism in CKD patients. They have been designed to have a more favorable side effect profile compared to calcitriol, particularly regarding hypercalcemia and hyperphosphatemia [2]. Paricalcitol (Zemplar®) and Doxercalciferol (Hectorol®) are key competitors in the CKD market, offering potential advantages in tolerability and efficacy for specific patient subgroups.
Phosphate Binders: In CKD patients, managing phosphate levels is paramount. Phosphate binders (e.g., calcium-based, non-calcium-based) are used alongside or in conjunction with Vitamin D therapy, creating a complex therapeutic regimen.
Calcimimetics: Agents like cinacalcet (Sensipar®) are used to treat secondary hyperparathyroidism in CKD patients on dialysis. Calcimimetics work by increasing the sensitivity of the calcium-sensing receptor on the parathyroid gland, thereby suppressing PTH secretion. Cinacalcet represents a non-Vitamin D-based approach to managing hyperparathyroidism and competes directly with calcitriol in this indication.

The competitive pressure from newer, more targeted therapies, particularly in the CKD space, necessitates that calcitriol's value proposition rests on its established efficacy, broad availability, and cost-effectiveness.

What are the Emerging Research and Development Opportunities for Calcitriol?

While calcitriol is a mature drug, ongoing research is exploring its potential in new therapeutic areas, which could represent future growth opportunities. These explorations are often preclinical or in early-stage clinical trials.

Oncology: Calcitriol and its analogues have demonstrated anti-proliferative, pro-apoptotic, and anti-angiogenic effects in cancer cells in vitro and in preclinical models. Research is investigating its role in various cancers, including breast, prostate, and colon cancer, often in combination with standard chemotherapy or targeted therapies [3].
- Mechanism: Calcitriol can bind to the Vitamin D receptor (VDR), which is expressed in many cancer cells. VDR activation can influence gene expression related to cell cycle regulation, differentiation, and apoptosis.
- Challenges: Systemic administration of high doses of calcitriol required for anti-cancer effects can lead to significant hypercalcemia, a dose-limiting toxicity. Development of VDR activators with a wider therapeutic window or targeted delivery systems is crucial.
Autoimmune Diseases: Calcitriol's immunomodulatory properties are being investigated for conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).
- Mechanism: Calcitriol can modulate T-cell differentiation (e.g., promoting T regulatory cells), reduce pro-inflammatory cytokine production, and enhance the function of antigen-presenting cells.
- Clinical Status: Clinical trials have been conducted or are underway to assess calcitriol's efficacy and safety in managing these complex immune-mediated disorders. Results have been mixed, highlighting the need for further research to define patient populations and optimal dosing.
Infectious Diseases: Some studies suggest calcitriol may play a role in innate immunity and could have beneficial effects in certain infectious conditions, including tuberculosis and viral infections.

These emerging applications are still in the investigational phase. Significant investment in clinical trials, regulatory approval processes, and overcoming existing safety concerns like hypercalcemia will be required for any new indications to reach the market.

What are the Regulatory Considerations and Pricing Dynamics?

The regulatory landscape for calcitriol is well-established, given its long history of use. However, any pursuit of new indications or novel formulations will trigger rigorous review processes.

FDA and EMA Approval: Calcitriol is approved by major regulatory bodies like the FDA and the European Medicines Agency (EMA) for its established indications. Generic approvals follow bioequivalence studies, which are generally less complex than initial drug approvals.
New Indication Approval: Pursuing new indications, such as in oncology or autoimmune diseases, requires extensive preclinical and clinical trials (Phase I, II, and III) to demonstrate safety and efficacy in the target population. This is a lengthy and costly process.
Post-Market Surveillance: Ongoing pharmacovigilance is required for all approved drugs to monitor for adverse events. For calcitriol, hypercalcemia remains a primary safety concern that necessitates careful patient monitoring and dose adjustment.
Pricing:
- Generic Pricing: The price of generic calcitriol is highly competitive, driven by manufacturing costs and market supply. Prices can vary significantly between manufacturers and regions. The average wholesale price (AWP) for generic calcitriol capsules (0.25 mcg) can be as low as $0.20-$0.50 per capsule, with intravenous formulations being more expensive but still subject to generic competition.
- Branded Pricing (Historical/Niche): Branded calcitriol or novel Vitamin D analogues used for specific indications (e.g., paricalcitol) command higher prices. For instance, paricalcitol injections can range from $50-$200 per dose depending on concentration and dosage.
- Reimbursement: Reimbursement policies by government payers (e.g., Medicare, Medicaid) and private insurers significantly influence market access and pricing. Inclusion on formularies often depends on demonstrated clinical utility and cost-effectiveness compared to alternatives.
- New Indication Pricing: If calcitriol gains approval for a new indication, particularly in areas like oncology or rare diseases, it could support premium pricing, contingent on demonstrating significant unmet need and superior efficacy or safety. However, the risk of hypercalcemia might limit the achievable price point even for new uses.

Understanding these dynamics is crucial for assessing the commercial viability of calcitriol in its current and potential future markets.

What are the Financial and Investment Considerations?

Investing in calcitriol requires a strategic perspective, acknowledging its mature market status while evaluating potential upside from R&D.

Mature Market Dynamics: The primary market for calcitriol is characterized by high generic penetration and price competition. Revenue growth from existing indications is likely to be modest, driven by volume increases in patient populations rather than significant price appreciation.
Cost of Goods Sold (COGS): For generic manufacturers, efficient API sourcing and manufacturing are critical to maintaining profitability. Lower COGS allows for competitive pricing and market share capture.
R&D Investment for New Indications: Companies seeking to develop calcitriol for new indications must commit substantial capital to R&D. The high failure rate in drug development means that investments in novel uses carry inherent risk.
Valuation Drivers:
- For Generic Manufacturers: Valuation is typically based on market share, manufacturing efficiency, and the ability to maintain competitive pricing in a high-volume, low-margin environment.
- For Companies Developing New Indications: Valuation would be heavily influenced by the perceived success probability of clinical trials, the potential market size for the new indication, and the strength of any remaining intellectual property (e.g., method of use patents).
Competitive Threat of Alternatives: The emergence of more targeted therapies for secondary hyperparathyroidism (e.g., paricalcitol, cinacalcet) poses a competitive threat that can erode calcitriol's market share in its primary indication, particularly if these alternatives offer superior tolerability or efficacy for specific patient subgroups.
Strategic Partnerships: Companies with strong manufacturing capabilities in generic calcitriol might explore strategic partnerships with academic institutions or smaller biotechs investigating novel applications, potentially sharing R&D costs and future revenues.

Investment decisions should weigh the stability of the existing generic market against the high-risk, high-reward potential of developing calcitriol for novel therapeutic areas.

Key Takeaways

Calcitriol is an established therapeutic agent with a stable market for chronic kidney disease (CKD)-related metabolic disorders and other bone-related conditions.
The drug is off-patent, leading to a highly competitive generic market with significant price pressure.
Key competitors in the CKD space include other Vitamin D analogues (paricalcitol, doxercalciferol) and calcimimetics (cinacalcet), which may offer improved tolerability.
Emerging research into calcitriol's applications in oncology and autoimmune diseases presents potential future growth opportunities, but these face significant clinical and regulatory hurdles, including hypercalcemia risk.
Investment analysis requires balancing the predictable revenue from the mature generic market against the high-risk, high-reward potential of R&D for new indications.

Frequently Asked Questions

What is the primary driver of current calcitriol demand? The primary driver is the management of secondary hyperparathyroidism and bone disease in patients with chronic kidney disease (CKD).
Are there any active patents protecting calcitriol itself? No, the patents for the calcitriol molecule have expired. Patents may exist for specific formulations or novel methods of use.
What are the main safety concerns associated with calcitriol therapy? The most significant safety concern is hypercalcemia, which can lead to serious cardiovascular and renal complications.
How does calcitriol compete with newer therapies for secondary hyperparathyroidism in CKD? It competes on cost-effectiveness and established efficacy, while newer agents like paricalcitol and cinacalcet offer potential advantages in tolerability and specific patient profiles.
What is the biggest obstacle to calcitriol's adoption in new indications like oncology? The primary obstacle is the risk of dose-limiting hypercalcemia, which requires careful management and potentially novel delivery systems or related compounds with a better therapeutic index.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Prescribing Information: Calcitriol Capsules. Retrieved from [FDA website - specific product label information would be linked here if publicly accessible and stable].

[2] Kestenbaum, B., & Hruska, K. A. (2004). Vitamin D analogues for the management of secondary hyperparathyroidism. Kidney International, 65(S96), S59-S66.

[3] Deeb, K. K., Shu, X., & Jones, S. N. (2007). Vitamin D endocrine system and cancer. European Journal of Pharmacology, 584(2-3), 195-207.

US Patents:	0
Applicants:	18
NDAs:	19

CALCITRIOL Drug Patent Profile

When do Calcitriol patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Calcitriol

AI Deep Research

Questions you can ask:

Summary for CALCITRIOL

US Patents and Regulatory Information for CALCITRIOL

Calcitriol: Market Landscape and Investment Fundamentals